Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined array key "thumbnail" in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 25
StackHealth / Eli Lilly launches Employer Connect to broaden GLP‑1 coverage

Eli Lilly's new program aims to boost employer coverage of GLP-1s

Shelby Livingston / endpoints - With insurance coverage of weight loss medications stalled, Eli Lilly has developed a program to give employers another way to pay for their workers' GLP-1 treatments. The pharma giant on Thursday announced the launch of ...

AI Summary: Eli Lilly unveiled an Employer Connect program designed to help employers expand coverage for GLP‑1–class weight‑loss drugs amid stalled insurer uptake. The initiative offers new contracting and access pathways for workplaces, addressing demand while prompting debate over whether it changes the underlying benefit‑design economics. It’s helpful—if you don’t expect a revolution.

#obesity #healthcare #pharmaceuticals #drugpricing #elililly #weightloss #healthcarefinance

Concerning rise in US teen obesity over a decade

2 months / medicalxpress

Obesity, treatment, and shame: What women really think about pharmacotherapy

2 months / medicalxpress

Structure Therapeutics Oral GLP-1 Obesity Drug Achieves ‘Injectable-Like Efficacy’ in Phase 2 Test

2 months / medcitynews / Frank Vinluan

Bariatric surgery volumes continue falling amid GLP-1 boom

2 months / beckershospitalreview / Paige Twenter

Structure Therapeutics reports more Phase 2 data for oral GLP-1

2 months / endpoints / Kyle LaHucik

At SXSW, Cuban and eMed CEO Draw Contrast Between Them and Other “Marketing” Companies

2 months / medcitynews / Arundhati Parmar

Fat cells burn energy to make heat, making them the next frontier of weight loss therapies

2 months / medicalxpress

Kroger pharmacies add Zepbound KwikPen

2 months / beckershospitalreview / Ella Jeffries

What happens when patients stop taking GLP-1 drugs? New study reveals real world insights

2 months / medicalxpress

Eli Lilly warns of risks tied to compounded tirzepatide with B12

2 months / beckershospitalreview / Ella Jeffries

3 updates on potential GLP-1 uses, risks

2 months / beckershospitalreview / Paige Twenter

Compounders prescribing GLP-1s put pricing pressure on Novo, Lilly

2 months / endpoints / Shelby Livingston

Lilly warns of impurity risk in certain compounded forms of Mounjaro and Zepbound

2 months / endpoints / Elizabeth Cairns

Carrum, Virta Join Forces on Employer Weight Management Solution

2 months / medcitynews / Marissa Plescia

Q&A: How small steps can help GLP-1 users build healthier habits

2 months / medicalxpress

Lilly plots GLP-1 pill production boost in China, $500M pledge to South Korea

2 months / endpoints / Anna Brown

Eli Lilly CEO David Ricks seeks 'exit velocity' for pharma's future

2 months / endpoints / Andrew Dunn

GLP-1 medication changes may support long-term weight management

2 months / medicalxpress

Wegovy may have highest 'eye stroke' and sight loss risk among semaglutide GLP-1 agonists

2 months / medicalxpress

2018 to 2025 saw rise in GLP-1 receptor agonist Rx for bariatric surgery-eligible patients

2 months / medicalxpress

Carrum Health teams up with Virta Health on a comprehensive weight loss solution

2 months / fiercehealthcare

Ascletis touts GLP-1 quarterly dosing data; Mineralys apnea Phase 2 misses

2 months / endpoints / ENDPOINTS

Mouse brain study reveals why blockbuster weight-loss drugs may work differently in females and males

2 months / medicalxpress

Digital nudges help GLP-1 users: Stanford

2 months / beckershospitalreview / Giles Bruce

Hims & Hers makes deal with Novo Nordisk as it shifts obesity strategy

2 months / fiercehealthcare

10 drugs poised to be global best-sellers in 2030

2 months / beckershospitalreview / Paige Twenter

AbbVie, Gubra post obesity data; Regeneron obesity drug succeeds in China

2 months / endpoints / ENDPOINTS

Amazon Pharmacy expands Zepbound access

2 months / beckershospitalreview / Ella Jeffries

Hims agrees to limit compounding, ending feud with Novo Nordisk

2 months / endpoints / Shelby Livingston

Novo, Hims strike GLP-1 deal after legal feud

2 months / beckershospitalreview / Ella Jeffries

Roche, Zealand Pharma Obesity Drug Meets Clinical Trial’s Weight Loss Goals, But Can It Compete?

2 months / medcitynews / Frank Vinluan

Lilly Employer Connect Adds Flexibility for Employers But Isn’t Revolutionary, Expert Says

2 months / medcitynews / Marissa Plescia

Eli Lilly's new program aims to boost employer coverage of GLP-1s

2 months / endpoints / Shelby Livingston

Back to Top / Saturday, March 7, 2026, 10:21 pm / permalink 20341 / 33 stories in 2 months /


Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61


Related Stories


Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Lilly’s next‑gen GLP‑1 posts compelling Phase 3 weight and A1C results / 2 months

Medicare unveils new option for covering weight‑loss drugs for seniors / 22 days

CMS delays Medicare GLP-1 pilot amid insurer skepticism / 5 wks

Compounding Pharmacy Sues Lilly and Novo Nordisk / 4 months

Lilly’s Zepbound bests Novo’s CagriSema in head‑to‑head obesity trial / 3 months

Novo launches high‑dose Wegovy in US at $399 for self‑pay patients / 7 wks

Trump Administration Secures Lower Obesity Drug Prices / 6 months

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Avian Influenza, Biotech, Diabetes, Hearing Loss and look for the RSS link.


↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.